The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS‐I Through IRS‐IV Studies as Background for the Current IRS‐V Treatment Protocols

Abstract

Purpose. To enumerate lessons from studying 4292 patients with rhabdomyosarcoma (RMS) in the Intergroup Rhabdomyosarcoma Study Group (IRSG, 1972–1997). Patients. Untreated patients < 21 years of age at diagnosis received systemic chemotherapy, with or without irradiation (XRT) and/or surgical removal of the tumor. Methods. Pathologic materials and treatment were reviewed to ascertain compliance and to confirm response and relapse status. Results. Survival at 5 years increased from 55 to 71% over the period. Important lessons include the fact that extent of disease at diagnosis affects prognosis. Re‐excising an incompletely removed tumor is worthwhile if acceptable form and function can be preserved. The eye, vagina, and bladder can usually be saved. XRT is not necessary for children with localized, completely excised embryonal RMS. Hyperfractionated XRT has thus far not produced superior local control rates compared with conventional, once‐daily XRT. Patients with non‐metastatic cranial parameningeal sarcoma can usually be cured with localized XRT and systemic chemotherapy, without whole‐brain XRT and intrathecal drugs. Adding doxorubicin, cisplatin, etoposide, and ifosfamide has not significantly improved survival of patients with gross residual or metastatic disease beyond that achieved with VAC (vincristine, actinomycin D, cyclophosphamide) and XRT. Most patients with alveolar RMS have a tumor‐specific translocation. Mature rhabdomyoblasts after treatment of patients with bladder rhabdomyosarcoma are not necessarily malignant, provided that the tumor has shrunk and malignant cells have disappeared. Discussion. Current IRSG‐V protocols, summarized herein, incorporate recommendations for risk‐based management. Two new agents, topotecan and irinotecan, are under investigation for patients who have an intermediate or high risk of recurrence.

References 22

1. 1.

   Arndt C., Tefft M., Gehan E., Anderson J., Jenson M., Link M., Donaldson S., Breneman J., Wiener E., Webber B. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol Oncol. 1997;19(2):124-129.

   Not in our library10.1097/00043426-199703000-00005

2. 2.

   Barr F. G. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997;19(6):483-491.

   Not in our library10.1097/00043426-199711000-00001

3. 3.

   Crist W. M., Garnsey L., Beltangady M. S., Gehan E., Ruymann F., Webber B., Hays D. M., Wharam M., Maurer H. M. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol. 1990;8(3):443-452.

   Not in our library10.1200/jco.1990.8.3.443

4. 4.

   Crist W., Gehan E. A., Ragab A. H., Dickman P. S., Donaldson S. S., Fryer C., Hammond D., Hays D. M., Herrmann J., Heyn R. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13(3):610-630.

   Not in our library10.1200/jco.1995.13.3.610

5. 5.

   Hays D. M., Lawrence W., Wharam M., Newton W., Ruymann F. B., Beltangady M., Maurer H. M. Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg. 1989;24(1):5-10.

   Not in our library10.1016/s0022-3468(89)80290-8

6. 6.

   Heyn R., Haeberlen V., Newton W. A., Ragab A. H., Raney R. B., Tefft M., Wharam M., Ensign L. G., Maurer H. M. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol. 1993;11(2):262-270.

   Not in our library10.1200/jco.1993.11.2.262

7. 7.

   Heyn R., Khan F., Ensign L. G., Donaldson S. S., Ruymann F., Smith M. A., Vietti T., Maurer H. M. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol. 1994;23(2):99-106.

   Not in our library10.1002/mpo.2950230206

8. 8.

   Heyn R., Newton W. A., Raney R. B., Hamoudi A., Bagwell C., Vietti T., Wharam M., Gehan E., Maurer H. M. Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol. 1997;15(1):69-75.

   Not in our library10.1200/jco.1997.15.1.69

9. 9.

   Kelly K. M., Womer R. B., Sorensen P. H., Xiong Q. B., Barr F. G. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol. 1997;15(5):1831-1836.

   Not in our library10.1200/jco.1997.15.5.1831

10. 10.

    Kuttesch J. F., Parham D. M., Luo X., Meyer W. H., Bowman L., Shapiro D. N., Pappo A. S., Crist W. M., Beck W. T., Houghton P. J. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol. 1996;14(3):886-900.

    Not in our library10.1200/jco.1996.14.3.886

11. 11.

    Lawrence W., Anderson J. R., Gehan E. A., Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer. 1997;80(6):1165-1170.

    Not in our library

12. 12.

    Lawrence W., Hays D. M., Heyn R., Beltangady M., Maurer H. M. Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors. World J Surg. 1988;12(5):676-684.

    Not in our library10.1007/bf01655884

13. 13.

    Malkin D., Li F. P., Strong L. C., Fraumeni J. F., Nelson C. E., Kim D. H., Kassel J., Gryka M. A., Bischoff F. Z., Tainsky M. A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-1238.

    Not in our library10.1126/science.1978757

14. 14.

    Mandell L., Ghavimi F., LaQuaglia M., Exelby P. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol. 1990;18(6):466-471.

    Not in our library10.1002/mpo.2950180606

15. 15.

    Maurer H. M., Beltangady M., Gehan E. A., Crist W., Hammond D., Hays D. M., Heyn R., Lawrence W., Newton W., Ortega J. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61(2):209-220.

    Not in our library10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l

16. 16.

    Maurer H. M., Gehan E. A., Beltangady M., Crist W., Dickman P. S., Donaldson S. S., Fryer C., Hammond D., Hays D. M., Herrmann J. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71(5):1904-1922.

    Not in our library10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x

17. 17.

    Neville H. L., Andrassy R. J., Lally K. P., Corpron C., Ross M. I. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg. 2000;35(6):961-964.

    Not in our library10.1053/jpsu.2000.6936

18. 18.

    Newton W. A., Soule E. H., Hamoudi A. B., Reiman H. M., Shimada H., Beltangady M., Maurer H. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol. 1988;6(1):67-75.

    Not in our library10.1200/jco.1988.6.1.67

19. 19.

    Pappo A. S., Lyden E., Breneman J., Wiener E., Teot L., Meza J., Crist W., Vietti T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol. 2001;19(1):213-219.

    Not in our library10.1200/jco.2001.19.1.213

20. 20.

    Ruymann F. B., Vietti T., Gehan E., Wiener E., Wharam M., Newton W. A., Maurer H. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol. 1995;17(4):331-337.

    Not in our library10.1097/00043426-199511000-00009

21. 21.

    Strong L. C., Williams W. R., Tainsky M. A. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol. 1992;135(2):190-199.

    Not in our library10.1093/oxfordjournals.aje.a116271

22. 22.

    Wolden S. L., Anderson J. R., Crist W. M., Breneman J. C., Wharam M. D., Wiener E. S., Qualman S. J., Donaldson S. S. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 1999;17(11):3468-3475.

    Not in our library10.1200/jco.1999.17.11.3468

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.